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ABSTRACT 
Background: Serotonergic raphe nuclei dysfunction has been documented in Parkinson’s disease, 
both in pathological and neuroimaging studies, and has been associated with scores of tremor and 
non-motor symptoms. However, no in vivo longitudinal investigations have been conducted to 
assess the rate of decline of raphe serotonin transporter availability in the early stages of the disease.  
Objective: To measure the rate of decline of raphe serotonin transporter availability over a two-
year interval in patients with recently diagnosed disease and its association with non-motor 
symptoms over time.  
Methods: Baseline and two-year follow-up 123ioflupane-fluoropropyl-carbomethoxy-3-beta-4-iodo-
phenyltropane (123I-FP-CIT) SPECT scans of 173 early Parkinson’s disease patients enrolled in the 
Parkinson’s Progressive Markers Initiative were analysed and non-motor symptoms scores 
recorded. 
Results: A 16.620.9% (meanSD) reduction in raphe serotonin transporter availability was found 
from baseline to two-year follow-up in the entire cohort. No differences in progression were found 
between tremor dominant and postural instability/gait difficulty phenotypes. At follow-up 34.1% of 
patients showed a moderate-to-severe reduction of raphe serotonin transporter availability with 
respect to the controls’ mean. We did not find any significant correlation between raphe serotonin 
transporter availability and scores of depression, excessive daytime sleepiness and REM sleep 
behaviour disorder. 
Conclusion: 123I-FP-CIT SPECT was able to measure longitudinal reductions in raphe serotonin 
transporter availability in the early phases of Parkinson’s disease. About four years after diagnosis,  
raphe serotonin transporter availability was significantly reduced in more than one third of the 
population, but does not appear to be correlated to non-motor symptoms at this stage. 
  
INTRODUCTION   
The raphe nuclei complex in the midline of the brainstem contains the majority of the serotonergic 
cell bodies in the brain [1,2]. The more rostral cell groups in the pontine and midbrain raphe, 
including the dorsal raphe nuclei, send extensive projections to the basal ganglia, frontal cortex, 
limbic system, and diencephalon, whereas the caudal raphe nuclei in the medulla project towards 
the spinal cord and brainstem. Pathological and functional abnormalities within the raphe 
serotonergic nuclei in Parkinson’s disease  (PD) have been well documented, both ex vivo [3,4], and 
in vivo with SPECT and PET serotonergic radioligands [5–8]. While these findings have been 
consistent in the advanced stages of the disease, less homogeneous results have been described in 
the early stages [9–13]. A recent study from our group on the large cohort of untreated PD patients 
with a diagnosis for less than two years recruited in the Parkinson’s Progressive Markers Initiative 
(PPMI) has reported a significant reduction of raphe serotonin transporter availability as measured 
by 123I-FP-CIT SPECT at this very early stage of disease [8].  However, a large number of patients 
still had levels of serotonin transporter availability comparable with those of age-matched healthy 
volunteers.   
In the PPMI, 123I-FP-CIT SPECT was performed at baseline and subsequent follow-ups as a 
measure of dopamine transporter availability. However, 123I-FP-CIT also binds non-selectively to 
serotonin transporters. de Win and colleagues [14] have validated the use of this tracer for the 
investigation of SERT-rich areas such as the raphe nuclei, where 123I-FP-CIT binds to 
somatodendritic serotonin reuptake transporters. 
The aims of the current study were to (i) assess the magnitude of raphe serotonin transporter 
availability reduction in this large cohort of early PD patients after a two-year follow-up; (ii) 
determine whether 123I-FP-CIT SPECT can be used to detect longitudinal changes in raphe 
serotonin transporter availability in PD and evaluate progression of raphe dysfunction from baseline 
to the two-year follow-up; iii) establish whether, over time, levels of raphe serotonin transporters 
are associated with scores of depression, excessive daytime sleepiness and REM sleep behaviour 
disorder. 
 
METHODS 
Patients 
123I-FP-CIT imaging and clinical data used in this analysis were available in the PPMI database 
(http://www.ppmi-info.org/data). The PPMI is an ongoing longitudinal, observational, multicentre 
international clinical study of early Parkinson’s disease patients aimed at identifying disease 
biomarkers. In order to enter the study, patients needed to have a diagnosis for less than two years, 
be untreated and show evidence of striatal dopamine transporter deficit on SPECT imaging (study 
protocol available at https://www.ppmi-info.org/study-design/research-documents-and-sops/) [15]. 
Our analysis was focused on the time span from baseline to the two-year follow-up. 
Two hundred and twenty-four patients had both baseline and two-year follow-up 123I-FP-CIT scans 
and clinical data available at the time of the analysis. The scan of 23 patients did not include the 
caudal raphe and 28 patients were taking serotonergic medications at the time of the scan; these 
patients were excluded from the analysis, while the remaining 173 were considered eligible. The 
baseline scans of 185 matched controls were available for this analysis. Follow-up SPECT scans for 
controls were not provided in the PPMI study.  
 
Clinical evaluations  
All patients underwent motor and non-motor assessments at baseline and two-year follow-up. All 
motor assessments were performed in the off-state. MDS-UPDRS part III was used to record tremor 
scores, as described in a previous paper from our group [8]. Patients were phenotypically classified 
as “Tremor Dominant (TD)”, “Postural Instability / Gait Difficulty (PIGD)” or “Indeterminate” 
according to Stebbins et al. classification [16]. 
Excessive daytime sleepiness (EDS) scores were obtained from the Epworth Sleepiness Scale [17], 
severity of rapid eye movement sleep behaviour disorder was assessed through the Rapid eye 
movement sleep Behaviour Disorder (RBD) Screening Questionnaire (RDBSQ) [18], and 
depressive features were screened with the Geriatric Depression Scale (GDS) [19]. 
 
123I-FP-CIT SPECT imaging protocol 
Both baseline and follow-up SPECT scans were analysed by the same investigator through a region 
of interest analysis, as detailed in a previous study from our group [8]. Briefly, 123I-FP-CIT SPECT 
was used to measure serotonin transporter availability in the raphe nuclei [14] and dopamine 
transporter availability in the putamen nuclei. Regions of interest (ROIs) were drawn on a single 
subject MRI template, encompassing caudal and rostral raphe nuclei, left and right putamen and the 
white matter within the occipital lobe, the latter used as reference region. The ROIs of the raphe 
nuclei were drawn according to their anatomical location as described by Hornung [20], with a 
rostral group in the midbrain and rostral pons (ROI average volume 591 mm3) and a caudal group in 
the caudal pons and medulla (ROI average volume 264 mm3). The ROIs were designed to be within 
the boundaries of the target regions so to minimize partial volume effect. The same ROIs template 
was used for both the baseline and follow-up analyses. The software Analyze 11.0 (Mayo Clinic) 
was used in order to load the ROIs of the MRI template onto the SPECT images in Montreal 
Neurological Institute (MNI) space. If a slight mis-alignment of a ROI was observed (e.g, slight 
lateral or medial shift), the ROI was slightly moved to center the anatomical structure, without 
changing their shape or size. This procedure was required for only a small number of patients and 
controls. For each region of interest the specific binding ratio (SBR) was calculated as follows:  
𝑆𝐵𝑅 =
(
𝑚𝑒𝑎𝑛 𝑟𝑒𝑔𝑖𝑜𝑛 𝑜𝑓 𝑖𝑛𝑡𝑒𝑟𝑒𝑠𝑡 𝑐𝑜𝑢𝑛𝑡𝑠
𝑝𝑖𝑥𝑒𝑙 ) − (
𝑚𝑒𝑎𝑛 𝑜𝑐𝑐𝑖𝑝𝑖𝑡𝑎𝑙 𝑐𝑜𝑢𝑛𝑡𝑠
𝑝𝑖𝑥𝑒𝑙 )
(
𝑚𝑒𝑎𝑛 𝑜𝑐𝑐𝑖𝑝𝑖𝑡𝑎𝑙 𝑐𝑜𝑢𝑛𝑡𝑠
𝑝𝑖𝑥𝑒𝑙 )
 
The sum of caudal and rostral raphe nuclei was used as the total raphe nuclei SBR. The average left 
and right putamen SBRs was used as the total Putamen SBR. As raphe specific binding ratios were 
not normally distributed, a ln(x + constant) transformation was successfully applied to normalize 
data. 
An analysis of individual PD patients was performed to identify those with raphe binding ratios 1.5 
standard deviations (SDs) and 2 SDs above and below the controls’ mean raphe binding ratio. A 
raphe binding <-1.5 SDs and >-2 SDs with respect to the controls’ mean was labeled as a moderate 
reduction, while a raphe binding <-2 SDs was labeled as a severe reduction. 
For each patient, the percentage change from baseline to the two-year follow-up of raphe and 
putamen was calculated as follows: 
        % 𝑐ℎ𝑎𝑛𝑔𝑒 = 100 𝑥 
(𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑟𝑒𝑔𝑖𝑜𝑛𝑎𝑙 𝑆𝐵𝑅) − (𝑓𝑜𝑙𝑙𝑜𝑤 𝑢𝑝 𝑟𝑒𝑔𝑖𝑜𝑛𝑎𝑙 𝑆𝐵𝑅)
(𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑟𝑒𝑔𝑖𝑜𝑛𝑎𝑙 𝑆𝐵𝑅)
 
 
Statistical Analysis 
Statistical interrogations were performed using the Statistical Package for the Social Sciences 
version 21 (SPSS 21). Means and standard deviations were calculated for clinical and demographic 
data of the PD cohort, while for the populations of controls these data have been reported in a 
previous study [8]. A Kolmogorov-Smirnov test was used in order to assess for normality of each 
variable used in the analysis. Raphe SBRs were not normally distributed and were transformed as 
previously described. 
The longitudinal analysis of raphe serotonin transporter availability, from baseline to the two-year 
follow-up, was assessed through a paired t-test. Independent t-tests were carried out in order to 
compare patients’ and controls’ raphe serotonin transporter availabilities at baseline and follow-up 
and to assess between-group differences in longitudinal reduction of raphe and putamen 123I-FP-
CIT binding; a Welch correction was used order to address for different group sizes [21]. 
A general linear model was applied in order to investigate the association between raphe transporter 
availability and non-motor symptoms ratings. In order to account for a possible influence of 
putamen dopamine transporter availability on these symptoms, this variable was held as a covariate 
of the model. 
 
RESULTS  
The clinico-demographic characteristics of the 173 PD patients studied are shown in Table 1.  In 
terms of age, gender, disease duration and raphe transporter availability, this group did not differ 
significantly from the cohort of 345 patients studied in a previous analysis conducted at baseline 
from our group [8]. (Supplementary table 1). 
 
Longitudinal evaluation of raphe serotonin transporter availability 
Both at baseline and two-year follow-up raphe serotonin transporter availability was significantly 
lower in PD patients compared with healthy controls (p<0.001) (Figure 1) and did not correlate 
with age (baseline: =-0.066, p=0.390; follow-up: =0.087, p=0.255) nor with disease duration 
(baseline =-0.100, p=0.222; follow-up =0.036, p=0.656).  
In 173 patients investigated at the two-year follow-up, we observed a significant reduction in raphe 
123I-FP-CIT specific binding ratio, reflecting serotonin transporter availability, compared to baseline 
(p<0.001) (Figure 1). The mean  SD reduction over the two years was 16.620.9%.  The majority 
of patients (120 of 173) underwent SPECT imaging at baseline and follow-up in the same season. 
We did not find significant differences in raphe SBR percentage reduction between patients who 
underwent their SPECT examinations in the same season compared to those who did not 
(16.519.0% vs 16.625.2%, t=0.16, p=0.987). We observed a significant association between the 
rate of decline of raphe serotonin transporter availability and that of putamen DAT availability in 
the whole PD cohort (=0.533, p-value<0.001). We found similar rates of reduction in raphe 
serotonin transporter availability in Tremor Dominant (TD, n=112) and Postural Instability/Gait 
Difficulty (PIGD, n=40) patients (14.719.9% vs 21.523.8%, p=0.113).  Instead, the latter 
experienced a significantly more severe reduction in putamen dopamine transporter availability 
(8.821.3% vs 19.115.1%, p=0.001). The 21 patients classified as “Indeterminate” according to 
Stebbins classification experienced a reduction in raphe binding of 17.020.6% and a reduction in 
putamen binding of 18.65.7%.   
Follow-up individual analysis showed a raphe SBR below -1.5 SDs and -2 SDs with respect to the 
controls’ mean in a larger proportion of patients compared to baseline (34.1% vs 9.8%). 
Additionally, at follow-up no patients showed SBRs >+1.5 SDs compared to the controls’ mean 
(Table 2). Interestingly, 42 of 150 patients (28.0%) who had a normal raphe SBR (within 1.5SDs 
of controls’ mean) at baseline were found to have a moderate (<-1.5 SDs) or severe (<-2 SDs) 
reduction at the two-year follow-up, lying below the -1.5 SDs compared to the controls’ mean. In 
this group of patients, the mean ( SD) reduction in 123I-FP-CIT SBR was 37.415.3%, versus 
16.620.9% of the entire population. At follow-up, 114 patients still presented a raphe SBR within 
normal range (1.5 SDs of the controls’ mean). Their mean (SD) rate of raphe SBR decline from 
baseline to follow-up was 12.116.1%. 
 
Clinical correlations 
As in our previous paper [22], at follow-up we found a significant inverse correlation between 
raphe serotonin transporter availability and rest tremor amplitude in 14 patients with an isolated rest 
tremor phenotype; in 112 Tremor Dominant (TD) patients we found significant inverse correlations 
between raphe serotonin transporter availability and rest tremor amplitude, constancy and index of 
rest tremor (data not shown). 
In order to assess for the effect of raphe serotonin on non-motor symptoms, a general linear model 
comprising raphe serotonin transporter availability and each of the non-motor symptoms considered 
was applied, holding putamen dopamine transporter binding as a covariate. In the entire population, 
we did not find any correlation between 123I-FP-CIT raphe SBR values and score of depression, 
EDS and RBD at follow-up (Supplementary Table 2). Scores of depression, EDS and RBD did 
not correlate with raphe serotonin transporter availability in a previous analysis conducted at 
baseline [8].  
 
DISCUSSION 
To our knowledge this is the first study to longitudinally assess in vivo raphe serotonin transporter 
availability in a large cohort of early de novo PD patients. In the entire cohort of 173 patients 
eligible for this study, we found a significant reduction of 123I-FP-CIT SBR in the raphe complex 
suggestive of a progressive decline in serotonin transporter availability in this region. The rate of 
reduction in mean raphe 123I-FP-CIT SBR in PD patients was 16.620.9% over a two-year interval. 
Interestingly, similar mean rates of decline in raphe 123I-FP-CIT binding were found in groups of 
patients with different motor phenotypes, suggesting that a reduction in raphe serotonin transporter 
availability occurs in all different motor phenotypes of PD. PIGD patients showed a greater decline, 
although not significant, compared to TD patients, probably suggesting that the former present an 
overall worse disease trajectory. Alternatively, patients with a TD phenotype may have shown 
lower rates of raphe SBR decline due to a more severe involvement of the raphe nuclei at baseline, 
as it has been shown previously in tremulous patients [8].  
Follow-up individual analysis of this cohort showed a progressive loss of serotonin transporter 
availability compared to baseline. In fact, the proportion of patients who had a raphe SBR lying 
below the -1.5 SDs of the controls’ mean at follow-up was more than doubled compared with 
baseline, reaching 34.1% of the population (59 patients). Forty-two of 150 patients (28%) who had 
a normal raphe binding at baseline were found to have a moderately or severely reduced raphe 
transporter binding at follow-up.  Interestingly, these patients experienced a marked mean reduction 
(37.415.3%) in 123I-FP-CIT SBR compared to the whole cohort. Conversely, 114 patients still had 
raphe SBR lying within 1.5 SDs of the controls’ mean at follow-up. Their mean reduction from 
baseline was 12.116.1%. These findings could contribute to explain the considerable variability in 
raphe transporter binding mean percentage reduction from baseline to the two-year follow-up 
(16.620.9%) in the entire cohort. They would also indicate that a substantial subgroup of patients 
might be more prone to develop an early loss of raphe serotonin transporter availability compared to 
the others. Over time these patients could develop a different motor and non-motor phenotype of 
PD with more severe serotoninergic impairment and specific therapeutic needs [23]. Other 
explanations for this large heterogeneity of raphe transporter availability and its progression in the 
early phases of PD remain to be investigated. It is possible that patients who have experienced a 
significant raphe transporter reduction in the early phases of the disease might show a low raphe 
123I-FP-CIT uptake at follow-ups and low reductions in longitudinal analyses. Also, low SBRs 
exhibited in some patients might suggest a floor effect of the SPECT technique used. Further 
analyses of the entire PPMI cohort once all patients have completed all longitudinal imaging 
assessments will help clarify this issue. A seasonal variability of serotonin transporter binding in 
many brain regions has been demonstrated in the general population living in temperate regions, 
with higher levels in the winter and lower levels in the summer [24]. In our study the majority of 
patients (120 out of 173) had their baseline and follow-up SPECT scans in the same season. No 
differences in raphe SBR reduction were shown between patients who underwent their SPECT 
examinations in the same season compared to those who did not.  
A previous 11C-DASB PET study from Politis et al. [7] evidenced a significant reduction in raphe 
serotonin transporter availability in 10 PD patients with a disease duration of 10+ years compared 
to healthy controls; no significant reductions were found in two separate groups of 10 PD patients 
with a disease duration of 0-5 years and 6-10 years, respectively. It must be acknowledged, 
however, that this transversal study involved a small number of patients and controls. Therefore, 
slight changes in the early phases of the disease, when the majority of the PD population still has a 
normal raphe serotonin transporter binding, might have been missed.  
Taken together, our findings suggest that in the early stages of PD 123I-FP-CIT SPECT can be used 
to detect the reduction of raphe serotonin transporter availability in single patients compared to a 
population of controls, and potentially to assess longitudinal changes in cohorts of patients. 
Additionally, in the clinical setting, 123I-FP-CIT SPECT could help identify subgroups of patients 
with more severe and faster decreases in SERT binding who might need more personalized 
treatment [23].  
Disruption of raphe serotonergic nuclei in Parkinson’s disease has been related to motor and non-
motor symptoms. Rest tremor has been found to be inversely associated with raphe nuclei serotonin 
transporter availability in several studies [8,22,25]. A PET study conducted with the serotonin 
transporter ligand 11C-DASB and the monoaminergic ligand 18F-DOPA suggested a diffuse 
dysfunction of neuronal networks related to wakefulness, including the raphe complex, in PD 
patients with EDS compared with patients without EDS [26]. Conversely, neuroimaging studies 
have produced conflicting evidence regarding the association between raphe serotonin transporter 
binding and depression, reporting either lower serotonin transporter in depressed patients [27], or 
higher in depressed patients [28] and patients with depressive symptoms [29], or not significantly 
different between depressed and non-depressed patients [10]. In our previous study, in which we 
analysed the baseline data of 345 patients enrolled in the PPMI study, we did not find any 
correlation between raphe 123I-FP-CIT SBR and questionnaire ratings of depression, EDS and RBD 
[8]. Similarly, in the current study we did not find any significant associations between raphe 123I-
FP-CIT SBR and scores of depression, EDS and RBD at follow-up. A recent PET study has 
suggested that cholinergic denervation in neocortical, limbic and thalamic areas could explain 
symptoms of RDB rather than dopaminergic and serotonergic dysfunctions [30].  As to depression 
and EDS, it is possible that these non-motor symptoms occur when a more severe impairment of 
raphe serotoninergic function is reached. Alternatively, it is possible that along with the disruption 
of raphe nuclei serotonergic transmission, other factors such as the involvement of other brain 
neurotransmitters and/or the effect of medications, are required for the onset of these symptoms. In 
conclusion, longer longitudinal studies are needed to clarify the relationship between raphe 
serotonin transporter availability and depression and EDS in PD.   
There are a number of limitations in our study that we should address. The smaller number of 
patients compared to the baseline cohort analysed by Qamhawi et al. (2015) [8]; however, the two 
populations did not differ significantly in terms of age, gender, disease duration and raphe 
transporter availability (Supplementary table 1). In the PPMI study, follow-up SPECT scans for 
controls were not provided, therefore we were unable to compare the rate of decline in PD patients 
against that of controls. This issue will need to be addressed in future studies. For the imaging 
analysis, a minority of PD patients (50 out of 173) underwent their baseline and follow-up SPECT 
scans in different seasons of the year. However, we compared raphe SBR reductions in patients who 
underwent their examination in the same season versus those who did not and we did not find any 
differences, suggesting that there was no significant seasonal influence on our findings. Finally, the 
main focus of this study was to investigate SERT availability in the serotonergic raphe nuclei, 
which contain the majority of the brain serotonergic cell bodies in the brain and according to the 
Braak staging are affected relatively early in the course of the disease.  The advantage of using 123I-
FP-CIT SPECT is that this imaging technique is widely available and therefore the evaluation of the 
raphe complex as proposed in this study can be reproduced in clinical practice.  However, 123I-FP-
CIT SPECT cannot be used to assess serotonin transporter availability in the cortical and 
subcortical serotoninergic terminals in the brain. Therefore, other imaging techniques with better 
spatial resolution and more selective SERT binding (e.g. 11C-DASB PET) in large cohorts are 
needed to better understand the extent of the involvement of the serotoninergic pathways in the 
early stages of PD. 
 
CONCLUSION 
In this study 123I-FP-CIT SPECT was able to detect the reduction of raphe serotonin transporter 
availability in single patients compared to a population of controls and to assess longitudinal 
changes. Overall, we found a significant progressive loss of raphe nuclei serotonin transporter 
availability in the PD population from baseline to the two-year follow-up and we showed an 
increasing prevalence of moderate-to-severe raphe serotonin transporter reduction, which was 
present in more than one third of this cohort. Within the first 4 years of disease, raphe 123I-FP-CIT 
binding was not associated with ratings of non-motor symptoms, i.e. depression, excessive daytime 
sleepiness and REM sleep behaviour disorder, suggesting that a more severe involvement and/or 
other factors (i.e. other neurotransmitter systems dysfunctions, effects of medications) are probably 
needed to trigger these symptoms. 
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Figure 1.  
Raphe binding in healthy controls and Parkinson’s disease patients at baseline and at the two-
year follow-up. SBR = specific binding ratio. Controls, n = 185; Parkinson’s disease patients, n = 
173. 
TABLES 
 
Table 1. Clinical and demographic characteristics of the 173 Parkinson’s disease patients included 
in the current analysis. 
Feature 173 PD patients 
Age, years, mean  SD, (range) at follow up 64.0  9.31 (41-85) 
Gender (M/F) 122/51 
Disease duration, months, mean  SD (range) at follow up 
54.88  6.66 (25-59) 
MDS- UPDRS III, 
mean  SD (range) 
Baseline 20.04  8.96 (4-51) 
24 months 25.7  11.4 (3-62) 
MDS- UPDRS total, 
mean  SD (range) 
Baseline 30.5  12.7 (7-68) 
24 months 41.2  16.4 (7-92) 
Hoehn and Yahr, mean 
 SD, range (1-3) 
Baseline 1.55  0.51 (1-3) 
24 months 1.78  0.54 (1-4) 
Medication Baseline No medication 
24 months No medication 31 (17.9%) 
Levodopa 44 (25.4%) 
Dopamine agonist 25 (14.5%) 
Other PD medication 34 (19.7%) 
Combination of two or 
more types of PD 
medication 
39 (22.5%) 
 
MDS-UPDRS = Movement Disorders Society – Unified Parkinson’s Disease Rating Scale. 
 
 
 
Table 2. Comparison between baseline and follow up Raphe SBR categories classified according to 
the controls’ mean  1.5 and 2 SDs in 173 patients with Parkinson’s disease. 
Raphe SBR in the PD cohort 
(compared to controls’ mean) 
Baseline (n = 173) 
% (n of patients) 
Follow-up (n = 173) 
% (n of patients) 
Raphe SBR > +1.5 SD 3.5% (6) 0 % 
 +1.5 SD < Raphe SBR < HCs 
mean 
31.8% (55) 
 
16.8% (29) 
HCs mean < Raphe SBR < -
1.5 SD 
54.9% (95) 
 
49.1% (85) 
-2 SD < Raphe SBR < -1.5 SD 5.8% (10)  20.8% (36) 
Raphe SBR < -2 SD 4.0% (7) 13.3% (23)  
 
SBR = specific binding ratio; HCs = healthy controls; SD = standard deviation 

SUPPLEMENTARY MATERIAL 
 
Supplementary Table 1 
 
Comparison of subjects characteristics between the group of 173 eligible patients at follow up and 
the group of 172 patients excluded from the follow-up analysis (total: 345 patients) 
 
Characteristic  Eligible vs Not Eligible P - Value 
Raphe 
transporter 
availability 
Mean  SD (t-test) 0.5841  0.1541 vs 0.5696  0.1627 0.394 
Chi-square * see bar chart 0.469 
Age (years  SD, t-test) 62.0  9.3 vs 62.3  10.4 0.793 
Disease duration (months  SD, 
t-test) 
30.9  6.7 vs 30.13  5.7 0.294 
Gender (M/F, Chi-square) 122/51 vs 109/63 0.171 
 
*: the distribution across 6 categories (mean  1.5 SDs and mean  2 SDs with respect to the 
controls’ mean) was tested through a chi-square test (see figure below). 
 
  
Supplementary Table 2. Follow up correlations between raphe serotonin transporter availability, 
depression (GDS), excessive daytime sleepiness (ESS) and REM sleep behavior disorder scores.  A 
general linear model comprising raphe transporter variable and each non-motor symptom was 
applied, holding putamen dopamine transporter variable as a covariate. 
 
Variables  
 
Depression 
(GDS Score) 
Excessive 
Daytime 
Sleepiness 
(ESS score) 
RBD 
(RBDSQ 
Score) 
Raphe serotonin 
transporter availability 
 
 -0.090 -0.001 -0.77 
P-Value 0.269 0.989 0.360 
 
GDS: Geriatric Depression Scale 
ESS: Epworth Sleepiness Scale 
RBDSQ: REM Sleep Behaviour Disorder Screening Questionnaire 
 
